Concepedia
Statistics
Publications
4
Citations
527
H-Index
Active since
1998
Affiliations
Institut Bergonié(Current)
AstraZeneca (France)
A. Fandi is an author at Institut Bergonié specializing in oncology, malignant neoplasms, and medicine.
Publications per year
1998–2003
Phase II trial of oxaliplatin as first-line chemotherapy in metastatic colorectal cancer patients. Digestive Group of French Federation of Cancer Centers.
Y. Bécouarn, Marc Ychou, Michel Ducreux et al. · Journal of Clinical Oncology · 1998 · 301 citations
Pharmacy, Oncology, Pharmacotherapy +12
Combination of Raltitrexed and Oxaliplatin Is an Active Regimen in Malignant Mesothelioma: Results of a Phase II Study
Karim Fizazi, H. Doubre, Thierry Le Chevalier et al. · Journal of Clinical Oncology · 2003 · 131 citations
Medicine, Oncology, Pharmacology +12
Phase II trial of chemotherapy with 5-fluorouracil, bleomycin, epirubicin, and cisplatin for patients with locally advanced, metastatic, or recurrent undifferentiated carcinoma of the nasopharyngeal type
A. Taamma, A. Fandi, N. Azli et al. · Cancer · 1999 · 56 citations
Medicine, Oncology, Pharmacotherapy +17
Multicenter non-randomized phase II study of raltitrexed (Tomudex) and oxaliplatin in non-pretreated metastatic colorectal cancer patients
J. F. Seitz, Jaafar Bennouna, B Paillot et al. · Annals of Oncology · 2002 · 39 citations
Medicine, Clinical Pharmacokinetics, Oncology +10
1–4 of 4